Localized Unresectable Thymic Carcinoma Treated with Induction Chemotherapy with Lenvatinib before Radiotherapy: A Case Report.

IF 1 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL
Shodai Fujimoto, Naoko Katsurada, Rie Sasaki, Takeaki Ishihara, Daisuke Hazama, Masatsugu Yamamoto, Motoko Tachihara
{"title":"Localized Unresectable Thymic Carcinoma Treated with Induction Chemotherapy with Lenvatinib before Radiotherapy: A Case Report.","authors":"Shodai Fujimoto, Naoko Katsurada, Rie Sasaki, Takeaki Ishihara, Daisuke Hazama, Masatsugu Yamamoto, Motoko Tachihara","doi":"10.2169/internalmedicine.4383-24","DOIUrl":null,"url":null,"abstract":"<p><p>Thymic carcinoma (TC) is a rare malignancy with limited treatment options. Lenvatinib, a novel multitarget kinase inhibitor, has recently been used to treat advanced or metastatic thymic carcinoma that cannot be surgically removed. To date, there have been no reports of lenvatinib being used as induction chemotherapy prior to radiotherapy in cases of localized, unresectable thymic carcinoma. We herein report an 85-year-old Japanese woman with localized unresectable thymic carcinoma who was treated with lenvatinib as induction chemotherapy before undergoing radiotherapy. Our findings suggest that lenvatinib may be a viable option for induction chemotherapy in similar clinical scenarios.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2169/internalmedicine.4383-24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Thymic carcinoma (TC) is a rare malignancy with limited treatment options. Lenvatinib, a novel multitarget kinase inhibitor, has recently been used to treat advanced or metastatic thymic carcinoma that cannot be surgically removed. To date, there have been no reports of lenvatinib being used as induction chemotherapy prior to radiotherapy in cases of localized, unresectable thymic carcinoma. We herein report an 85-year-old Japanese woman with localized unresectable thymic carcinoma who was treated with lenvatinib as induction chemotherapy before undergoing radiotherapy. Our findings suggest that lenvatinib may be a viable option for induction chemotherapy in similar clinical scenarios.

放疗前使用乐伐替尼诱导化疗治疗局部未切除胸腺癌:病例报告。
胸腺癌(TC)是一种罕见的恶性肿瘤,治疗方案有限。来伐替尼是一种新型多靶点激酶抑制剂,最近被用于治疗无法手术切除的晚期或转移性胸腺癌。迄今为止,还没有关于来伐替尼在局部无法切除的胸腺癌放疗前用作诱导化疗的报道。我们在此报告了一名85岁的日本女性患者,她患有局部不可切除的胸腺癌,在接受放疗前使用了来伐替尼作为诱导化疗。我们的研究结果表明,在类似的临床情况下,来伐替尼可能是一种可行的诱导化疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Internal Medicine
Internal Medicine 医学-医学:内科
CiteScore
1.90
自引率
8.30%
发文量
0
审稿时长
2.2 months
期刊介绍: Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信